Against Cervical Cancer, Vaccine Is a New Beginning, India’s Historic Step Toward Elimination
With the Nationwide Launch of HPV Vaccination for Adolescent Girls, India Takes a Decisive Step in a Global Effort to Eliminate a Disease That Claims Thousands of Lives Each Year
On February 28, India took a decisive and historic step in public health with the nationwide launch of Human Papillomavirus (HPV) vaccination for adolescent girls. This signals India’s commitment to eliminating cervical cancer, a disease that is easily preventable, yet continues to claim thousands of lives every year.
Globally, cervical cancer is the fourth most common cancer among women, with approximately 660,000 new cases and 350,000 deaths occurring each year. While many high-income countries have controlled cervical cancer rates through screening and vaccination programmes, the burden remains high in India. This is not a failure of intent but a reflection of the scale of the challenge—and the significance of the step now being taken.
The Burden India Bears
India bears one of the heaviest burdens of cervical cancer globally. It is the second most common cancer among Indian women and the third most common cancer overall in the country. Each year, India reports more than 78,000 new cases and almost 43,000 deaths. These are not abstract statistics. They are mothers, daughters, sisters, wives—women whose lives are cut short by a disease that we know how to prevent.
The tragedy is compounded by the fact that cervical cancer is one of the most preventable forms of cancer. Unlike many other cancers, the risk factors are well understood, the progression from infection to disease is slow, and the tools for prevention—vaccination and screening—are available and effective. Yet for decades, these tools have not reached the women who need them most.
Most cervical cancers are caused by an infection of the genital tract with the Human Papillomavirus. HPV is a common virus, and most sexually active individuals will contract it at some point in their lives. In most cases, the immune system clears the infection without consequence. But when high-risk types persist, they can cause cellular changes that eventually lead to cancer.
Unlike many other cancers, the risk of developing cervical cancer can be modified and reduced. The risk factors include early age of marriage, early initiation of sexual activity, multiple pregnancies, tobacco use, and poor genital hygiene—all of which are related to increased chances of infection. Most of these risk factors can be addressed through awareness, screening, and vaccination.
The Global Elimination Target
The World Health Organization has declared cervical cancer as the first cancer to be eliminated globally. This is an ambitious goal, but it is achievable. The WHO has set a clear elimination target: reducing the cancer rate to fewer than 4 new cases per 100,000 women per year.
The WHO’s global elimination efforts outline the “90–70–90” strategy: 90 per cent of girls to be fully vaccinated with HPV vaccine by age 15; 70 per cent of women to be screened with a high-performance test at ages 30 and above; and 90 per cent of women identified with disease to receive appropriate treatment.
India’s vaccination launch is a crucial step towards achieving these targets. But it is only one step. The other two pillars—screening and treatment—must be strengthened alongside vaccination. Without screening, women who are already infected will continue to develop cancer. Without treatment, even those identified with disease will not survive.
The Science of the Vaccine
HPV vaccines have a strong global safety record. The most commonly seen side effects are mild pain, redness, or swelling in the arm where the shot is given. Very rarely, the vaccinated girl may feel dizzy for a short time, just like with other vaccines. These are minor inconveniences compared to the disease they prevent.
The cervical cancer vaccine was first licensed 20 years ago, and has undergone rigorous scrutiny and evaluation since its licensure. Over 140 countries around the world have implemented vaccination against HPV infections. The data from millions of doses administered worldwide has confirmed its safety and effectiveness.
The most significant evidence over the past decade came from studies that demonstrated that even a single dose of HPV vaccine provides long-term protection. There are over 15-year-long clinical trials and follow-up studies, of which the Tata Memorial Centre has also been a part, that have proven that a single dose of HPV vaccine ensures safe, effective, and long-term protection in Indian populations against cervical cancers.
This research is crucial. A single-dose regimen simplifies logistics, reduces costs, and makes large-scale implementation feasible. It means that India can vaccinate millions of girls with a single visit, rather than requiring multiple doses over months. This is particularly important for reaching girls in remote and underserved areas.
The Global Experience
Around the world, cervical cancer rates have been declining due to improved awareness, screening, and vaccination. However, progress is not uniform. In India, urban areas have shown some decline due to factors such as improved hygiene, yet large rural and underserved populations continue to present with advanced cervical cancer disease.
Global experience teaches us that progress in cervical cancer control can stall if vaccination coverage is not ensured. In some countries that had significantly reduced cervical cancer burden, gaps in immunisation or disruptions in public health programmes have shown resurgence of cervical cancer cases.
Australia is often cited as a success story. The country is on track to eliminate cervical cancer within the next decade, thanks to a comprehensive programme that includes school-based vaccination and widespread screening. But even in Australia, there are concerns about coverage gaps and the need for continued vigilance.
Elimination requires sustained efforts and ensuring widespread coverage of HPV vaccination. It is not enough to launch a programme; the programme must be maintained, year after year, until the virus is driven out of circulation.
India’s Opportunity
India’s decision to introduce HPV vaccination is scientifically sound, cost-effective, and an ethical-moral imperative. It is a step towards ensuring a healthy female population. Combined with strengthened screening programmes and assured treatment access, vaccination can dramatically reduce the suffering caused by cervical cancer within the span of a generation.
The timing is right. India has built a robust immunisation infrastructure through the Universal Immunisation Programme. It has a network of trained health workers, cold chain systems, and supply chains that can deliver vaccines to the remotest corners of the country. The HPV vaccine can ride on this infrastructure.
But there are challenges. Reaching 90 per cent coverage of girls by age 15 will require more than infrastructure. It will require addressing vaccine hesitancy, overcoming cultural barriers, and ensuring that families understand the importance of protecting their daughters. It will require engaging schools, community leaders, and healthcare providers.
The cost is also a consideration. HPV vaccines are expensive, and vaccinating millions of girls will require significant financial commitment. But the cost of inaction is far higher. The cost of treating cervical cancer—the surgeries, radiation, chemotherapy, and palliative care—dwarfs the cost of prevention. And the human cost—the lives lost, the families shattered—is incalculable.
The Path Forward
The nationwide launch of HPV vaccination is a beginning, not an end. The work of achieving high coverage, of strengthening screening programmes, of ensuring treatment for those who need it—this work lies ahead.
The WHO’s 90–70–90 targets provide a roadmap. For India, achieving these targets will require:
First, sustained political commitment. Elimination will take a generation, and programmes must survive changes in government and policy priorities.
Second, adequate funding. Vaccination, screening, and treatment must be adequately resourced, not as one-time investments but as ongoing programmes.
Third, community engagement. Families must understand the importance of vaccination, and women must understand the importance of screening. This requires culturally appropriate communication, delivered through trusted messengers.
Fourth, health system strengthening. Screening and treatment require functioning health systems—with trained personnel, working equipment, and reliable supplies.
Fifth, data systems. To track progress, to identify gaps, to target resources effectively, India needs robust data on vaccination coverage, screening rates, and treatment outcomes.
Conclusion: A Historic Step
The nationwide launch of HPV vaccination marks a historic step in India’s public health journey. It is a recognition that prevention is better than cure, that investing in the health of girls today will yield dividends for generations.
Cervical cancer is a disease of inequity. It strikes hardest where healthcare is weakest, where awareness is lowest, where women have the fewest resources. By launching this vaccination programme, India is declaring that it will not accept this inequity. It is committing to protecting its daughters, regardless of where they live or what their families can afford.
The road ahead is long. Elimination will not happen overnight. There will be challenges, setbacks, and obstacles. But the journey has begun. And with this vaccine, India has taken a decisive and historic step towards a future where no woman dies from a disease that we know how to prevent.
Q&A: Unpacking India’s HPV Vaccination Programme
Q1: What is the scale of cervical cancer burden in India?
A: Cervical cancer is the second most common cancer among Indian women and the third most common cancer overall in the country. India reports more than 78,000 new cases and almost 43,000 deaths annually. This is one of the heaviest burdens globally. Globally, cervical cancer is the fourth most common cancer among women, with approximately 660,000 new cases and 350,000 deaths each year.
Q2: What causes cervical cancer, and why is it preventable?
A: Most cervical cancers are caused by an infection of the genital tract with the Human Papillomavirus (HPV). Unlike many other cancers, the risk of developing cervical cancer can be modified and reduced. Risk factors include early age of marriage, early sexual activity, multiple pregnancies, tobacco use, and poor genital hygiene. Through vaccination, screening, and awareness, these risks can be addressed.
Q3: What is the WHO’s elimination strategy for cervical cancer?
A: The WHO has declared cervical cancer as the first cancer to be eliminated globally, with a target of reducing the cancer rate to fewer than 4 new cases per 100,000 women per year. The “90–70–90” strategy requires: 90 per cent of girls fully vaccinated with HPV vaccine by age 15; 70 per cent of women screened with a high-performance test at ages 30 and above; and 90 per cent of women identified with disease receiving appropriate treatment.
Q4: What evidence supports the HPV vaccine’s safety and effectiveness?
A: HPV vaccines have a strong global safety record over 20 years of use, with over 140 countries implementing vaccination programmes. The most significant evidence comes from studies showing that even a single dose provides long-term protection. Over 15-year-long clinical trials, including those conducted by the Tata Memorial Centre, have proven that a single dose ensures safe, effective, and long-term protection in Indian populations.
Q5: What are the key challenges in implementing the vaccination programme?
A: Key challenges include: reaching 90 per cent coverage of girls by age 15 requires addressing vaccine hesitancy and cultural barriers; ensuring families understand the importance of vaccination; engaging schools, community leaders, and healthcare providers; securing sustained funding; strengthening screening and treatment systems; and building robust data systems to track progress. However, India’s existing Universal Immunisation Programme infrastructure provides a foundation for delivery.
